Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial

por Feils, A. S., Erbe, A. K., Birstler, J., Kim, K., Hoch, U., Currie, S. L., Nguyen, T., Yu, D., Siefker-Radtke, A. O., Tannir, N., Tolaney, S. M., Diab, A., Sondel, P. M.
Publicado 2023

Rituximab response in follicular lymphoma: contributions from KIR 2DS1 and HLA-C

por Erbe, A K, Wang, Wei, Grzywacz, B, Ranheim, E A, Hank, J A, Kim, K, Carmichael, L, Seo, S, Mendonca, E A, Song, Y, Hong, F, Gascoyne, R D, Paietta, E, Horning, S H, Kahl, B, Sondel, P M
Publicado 2013